Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Evotec Leverages Infectious Diseases Space With Sanofi R&D Deal

Executive Summary

Evotec's CEO tells Scrip its pact with Sanofi to develop an infectious disease pipeline could offer a commercially viable approach to battling the global AMR crisis.

Related Content

Alarm As Novartis Exits Antibiotics Space
Deal Watch: BridgeBio To Launch New Subsidiary Around Rare Disease Candidate Obtained From Alexion
Evotec And Arix Bridge Gap With Latest Cancer Funding
Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis
Novo $165m Superbug Fund is Fillip For Antibiotic Start-Ups
Evotec Rides Megatrend In Outsourced Innovation By Buying Aptuit CRO
13 Pharmas Sign Roadmap For Antibiotic Reform – But What Do They Want?
UN Countries Make Bold Pledges On AMR, Including Funding For R&D Into New Drugs and Diagnostics


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts